Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial

Medicine and Dentistry

• Transitional Cell Carcinoma 100%
• Observation 100%
• Muscle 100%
• Atezolizumab 100%
• Patient 91%
• Adverse Event 33%
• Neoadjuvant Chemotherapy 33%
• Therapeutic Procedure 25%
• Neoplasm 25%
• Disease Free Survival 25%
• Oncology 16%
• Adjuvant Therapy 16%
• Inpatient 16%
• Adjuvant Chemotherapy 16%
• Cisplatin 16%
• Combination Therapy 8%
• Death 8%
• Voice 8%
• Immunocompetent Cell 8%
• Follow up 8%
• Nephroureterectomy 8%
• Hazard Ratio 8%
• Lymph Node 8%
• Hospital 8%
• Urinary Tract Infection 8%
• Radiation Therapy 8%
• Programmed Death-Ligand 1 8%
• Safety Assessment 8%
• Acute Respiratory Distress Syndrome 8%
• Intention-to-Treat Analysis 8%
• Retroperitoneal Lymph Node Dissection 8%
• Recurrence Risk 8%
• Cystectomy 8%
• Cancer Staging 8%
• Anemia 8%
• Pyelonephritis 8%
• Radical Surgery 8%

Pharmacology, Toxicology and Pharmaceutical Science

• Pyelonephritis 8%
• Adult Respiratory Distress Syndrome 8%